GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)

GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a variation to the conditional marketing authorisation for Tyverb® (lapatinib) in the European Union for a new therapeutic indication. Tyverb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor.

Issued: Wednesday 23 June 2010, London UK

GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a variation to the conditional marketing authorisation for Tyverb® (lapatinib) in the European Union for a new therapeutic indication. Tyverb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503